The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double Blind Placebo Controlled Study.

Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL
Department of Diabetes and Endocrinology, University of Hull, Hull, UK; Department of Clinical Biochemistry, Hull Royal Infirmary, Hull, UK; Department of Obstetric Ultrasound, Hull & East Yorkshire Women’s & Children’s Hospital, Hull, UK.
Source J Clin Endocrinol Metab 2008 Oct 21.

Abstract Context: Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular morbidity whereas statins are proven to reduce cardiovascular mortality and morbidity through lipid lowering and perhaps through their pleotrophic effects. Statins can also reduce testosterone in vitro by inhibiting ovarian theca-interstitial cell proliferation, steroidogenesis and reducing inflammation in vivo.

Objective: To assess the effect of atorvastatin on inflammatory markers, insulin resistance and biochemical hyperandrogenemia in patients with PCOS.
Design: Randomised, double blind placebo controlled study.
Setting: Tertiary care setting in United Kingdom.
Patients: Forty medication naïve patients with PCOS and biochemical hyperandrogenaemia.
Methods: Patients were randomised to either atorvastatin 20mg daily or placebo.
Main outcome measures: The primary end point of the study was a change in the inflammatory marker hsCRP. The secondary end points were a change in insulin resistance and total testosterone.
Results: After 12 weeks of atorvastatin there was a significant reduction (mean+/-SEM) in total cholesterol (4.6+/-0.2 vs. 3.4+/-0.2 mmol/L,p<0.01), LDL cholesterol (2.9+/-0.2vs.1.8+/-0.2 mmol/L,p<0.01), triglycerides (1.34+/-0.08vs.1.08+/-0.13mmol/L,p<0.01), hsCRP (4.9+/-1.4vs.3.4+/-1.1mg/Lp=0.04), free androgen index (13.4+/-0.6vs.8.7+/-0.4 p<0.01), testosterone[4.1+/-0.2vs.2.9+/-0.1 nmol/Lp<0.01) and insulin resistance as measured by HOMA-IR(3.3+/-0.4vs.2.7+/-0.4). There was a significant increase in SHBG (31.1+/-1.0vs.35.3+/-1.2 nmol/L,p<0.01). There was a positive correlation between the reduction in HOMA-IR in the atorvastatin group with the reduction in triglycerides and the reduction of FAI. There was a significant deterioration of HOMA-IR in the placebo group (3.0+/-0.4vs.3.8+/-0.5).
Conclusions: This study suggests that atorvastatin is effective in reducing inflammation, biochemical hyperandrogenemia and metabolic parameters in patients with polycystic ovary syndrome after a 12 week period.

PubMed ID 18940877

Next Steps

Becoming victorious over the symptoms of Polycystic Ovary Syndrome is not easy, but you can overcome your PCOS symptoms to live the life you deserve.

It takes strength, courage, and perseverance. It can be challenging and that’s why Insulite Health created this website. It's has information and resources that will help you balance your hormones and reverse PCOS symptoms.

So take these next steps now! Use the links below to learn how to make the changes that will transform your health and your life forever.

  1. Read more about PCOS. Search our 1300 page PCOS library.
  2. Join our Facebook Group right now!  Pose your questions to this group of like-minded women and get the support you need.
  3. Take the PCOS Quiz! Get your PCOS score and assess your risk.  
  4. Learn more about the Insulite 5-Element PCOS Solution

Insulite Health, is committed to helping women reverse their symptoms of hormone imbalance. Scientific research has revealed that this imbalance can be a primary cause of many devastating health symptoms. Hormone Imbalance can also underlie the increased risk factors for PCOS (Polycystic Ovarian Syndrome) - a major source of serious diseases as well as cause of excess weight gain, adult acne, unwanted facial hair, depression, anxiety, and heartbreaking female infertility.

©Insulite Health, Inc., empowers women with PCOS to transform their lives through a process of healing with the 5-Element PCOS System – a complete solution for helping women reverse the symptoms of PCOS and hormone imbalance.